Why Crispidea Report
This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
Industry Analysis
Novartis’s View: Novartis frames the deal as a strategic move to strengthen its late
stage neuroscience pipeline and expand leadership in RNA therapeutics by adding
Avidity’s AOC platform for targeted muscle delivery and three late-stage programs
(DM1, FSHD, DMD).
Emerging Trends
Avidity Biosciences, Inc. (RNA.O) is a clinical-stage biopharmaceutical company
revolutionizing RNA therapeutics through its proprietary Antibody Oligonucleotide Conjugate (AOC ) platform, targeting the root causes of rare neuromuscular diseases and expanding into precision cardiology and
immunology.
CrispIdea Outlook
While Novartis achieved 7% constant currency sales growth in Q3FY25, exclusion of 9% points from gross-to-net adjustments reveals underlying operational growth of ~9%. Management guidance forecasts high single-digit sales growth in 2025 and low-teens coreoperating income growth.
Table of Content
Executive Summary
• Executive Summary………………….…………………………………………………………..3
• Deal Overview………………………….………………………………………………………….5
• Business Rationale………………………………………………………………………………..6
• Company Overview – Avidity Biosciences..….………….………………………….13
• Company Overview – Novartis AG…….…..………….…………………………….…..2
Disclaimer
This report was produced by a member company of the Crispidea. This report is for the use of intended recipients only and may not be reproduced (in whole or in part) or delivered or transmitted to any other person without our prior written consent. By accepting this report, the recipient agrees to be bound by the terms and limitations set out herein.
